Koranyi National Institute For Pulmonology
- Address
- lock Available on a paid plan
Koranyi National Institute For Pulmonology - Leading European Center for Lung Cancer and Respiratory Disease Research
The Koranyi National Institute For Pulmonology is a distinguished research center specializing in advanced respiratory medicine and oncology. With extensive involvement in cutting-edge clinical trials, the institute focuses on developing novel therapeutic approaches for non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), and complex pulmonary conditions. The center's research portfolio encompasses innovative immunotherapy combinations, targeted molecular therapies, and diagnostic advancement studies.
- Advanced Non-Small Cell Lung Cancer treatment with KRAS G12C inhibitors, pembrolizumab combinations, and antibody-drug conjugates across various disease stages
- Small Cell Lung Cancer research including novel bispecific T-cell engagers and multimodal treatment strategies for extensive and relapsed disease
- Severe Eosinophilic Asthma and Interstitial Lung Disease investigations, including systemic sclerosis-associated ILD and idiopathic pulmonary fibrosis
- Innovative diagnostic technologies for early lung cancer detection using breath biopsy analysis and biomarker identification
The institute demonstrates particular expertise in evaluating precision oncology approaches, including ROS1-positive and KRAS G12C-mutated lung cancers, as well as investigating next-generation delivery systems such as subcutaneous immunotherapy formulations. Their research extends to evaluating stereotactic body radiation therapy combined with immunotherapy for early-stage disease, and neuropathic pain management studies, reflecting a comprehensive approach to pulmonary and related systemic conditions affecting patient quality of life.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 6 therapeutic areas and 15 of 122 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 121 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 19 by active trials.
- 1AstraZeneca AB9active
lock +18 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Merck Sharp & Dohme LLC18trials
lock +11 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 332 other sites in Hungary
Therapeutic Area Benchmark — Hungary
Select a therapeutic area to compare against other sites in Hungary.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Hungary
Market Share
Country: Hungary
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Koranyi National Institute For Pulmonology
lock Showing 1 of 83 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A parallel-group treatment, proof-of-concept Phase 2, multicenter, double-blind, randomized 2 arm clinical trial to investigate the efficacy and safety of subcutaneous NT 201 injections compared with placebo injections in decreasing pain intensity in male and female participants aged 18 years and older with moderate or severe chronic neuropathic pain due to postherpetic neuralgia or peripheral nerve injury. | Merz Therapeutics GmbH | Phase II | Not Recruiting | Oct 2023 | Jun 2025 |
IMP list
lock Showing 1 of 122 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 34 | Unknown | 2015-11-06 | 2026-06-11 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.